Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLNR | O43193 | 1/20 | 0.87 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.87 |
| ▸ | LMNA | P02545 | 1/20 | 0.87 |
| ▸ | CTSD | P07339 | 1/20 | 0.87 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.87 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.87 |
| ▸ | CNR1 | P21554 | 1/20 | 0.87 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.87 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.87 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.63 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.63 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.63 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.63 |
| ▸ | KCND3 | Q9UK17 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13567479 | 1.00 | MLNR (0.87) | MLNRABCB11LMNACTSDCYP3A4 | |
| SCHEMBL14263372 | 0.94 | MLNR (0.76) | MLNRABCB11LMNACTSDCYP3A4 | |
| SCHEMBL13567472 | 0.94 | MLNR (0.76) | MLNRABCB11LMNACTSDCYP3A4 | |
| SCHEMBL13567461 | 0.93 | MLNR (0.75) | MLNRABCB11LMNACTSDCYP3A4 | |
| Amprenavir SCHEMBL2671137 | 0.93 | MLNR (1.00) | MLNRABCB11LMNACTSDCYP3A4 | |
| Amprenavir SCHEMBL20451345 | 0.93 | MLNR (1.00) | MLNRABCB11LMNACTSDCYP3A4 | |
| Amprenavir SCHEMBL3174937 | 0.93 | MLNR (1.00) | MLNRABCB11LMNACTSDCYP3A4 | |
| Amprenavir SCHEMBL34151 | 0.93 | MLNR (1.00) | MLNRABCB11LMNACTSDCYP3A4 | |
| Amprenavir SCHEMBL1388821 | 0.93 | MLNR (1.00) | MLNRABCB11LMNACTSDCYP3A4 | |
| Amprenavir SCHEMBL10276771 | 0.93 | MLNR (1.00) | MLNRABCB11LMNACTSDCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090312318-A1 | THERAPEUTIC COMPOUNDS AND METHODS | GILEAD SCIENCES, INC. | 2009-12-17 | — | — | US | disclosed |
| US-20090312318-A1 | THERAPEUTIC COMPOUNDS AND METHODS | GILEAD SCIENCES, INC. | 2009-12-17 | — | — | US | disclosed |
| US-20080070910-A1 | Therapeutic compounds and methods | GILEAD SCIENCES, INC. | 2008-03-20 | — | — | US | disclosed |
| WO-2008013834-A1 | BISFURANYL PROTEASE INHIBITORS | GILEAD SCIENCES, INC., (US) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312318-A1 | THERAPEUTIC COMPOUNDS AND METHODS | SERPINB1, ABCC1, SERPINB6 | MLNR 1554/4885ABCB11 282/4885LMNA 741/4885 |
| US-20080070910-A1 | Therapeutic compounds and methods | SERPINB1, ABCC1, SERPINB6 | MLNR 1554/4885ABCB11 282/4885LMNA 741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.